Evidence map›Paper›PMID 42305292›Full record

ArticleArchives of medical science : AMS2026

The effect of beinaglutide on visceral fat and body weight in obese type 2 diabetic patients.

Gui-Ying Wang, Hui-Qin Wang, Feng-Juan Zhang, Ai-Fu Jiao, Ying-Yu Li, Ji-Min Zhang, Zheng-Li Huang, Yan-Hong Gao, Yan-Jun Chi, Cun-Ming Ma and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gui-Ying WangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Hui-Qin WangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Feng-Juan ZhangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Ai-Fu JiaoDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Ying-Yu LiDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Ji-Min ZhangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Zheng-Li HuangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Yan-Hong GaoDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Yan-Jun ChiDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Cun-Ming MaDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Jian-Dong XinDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Ai-Xu DuanDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Tao MengDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Yin-Bing WangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Glucagon-like peptide-1 (GLP-1) analogues could induce clinically significant weight loss in obese patients with type 2 diabetes mellitus (T2DM). Beinaglutide is a GLP-1 analogue that is fully homologous to human GLP-1. This study aims to investigate the clinical efficacy of beinaglutide in visceral fat, weight loss and blood glucose in patients with T2DM and obesity. Material and methods: One hundred and seven obese patients with T2DM, according to the World Health Organisation's (WHO) diagnostic criteria, were treated with beinaglutide. After 12 weeks, changes in visceral fat (VF) were analysed using DUALSCAN. Body weight, body mass index (BMI), glycated haemoglobin (HbA Results: The baselines for BMI and VF areas were 32.8 ±5.2 kg/m Conclusions: Beinaglutide effectively reduced VF, body weight, and blood glucose in obese patients with T2DM. Beinaglutide doses should be individualised because appropriate doses varied widely. A lack of GLP-1 might be responsible for the onset of obesity in patients with T2DM. T2DM and obesity are related not only to insulin deficiency/insulin resistance but also to GLP-1 deficiency, which may cause obesity in patients with T2DM.

Indexed as

glucagon-like peptide-1obesitytype 2 diabetesvisceral fatweight loss

Identifiers

PMID42305292
PMCPMC13266512

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.